The present invention relates to novel functionalized morpholinyl anthracycline derivatives having cytotoxic activity and useful in the treatment of diseases such as cancer, cell proliferative diseases and viral infections. The present invention also provides a method for producing the compound, a pharmaceutical composition containing the compound, and a method for treating a disease using the compound, or a pharmaceutical composition containing the compound. The invention also relates to the use of said derivatives in the production of conjugates. The morpholinyl anthracycline derivative has the formula Ant-LWZ-RM (I) (wherein RM is absent or is a reactive moiety； Z is absent or is a peptide linker, non- A peptide linker or a peptide-non-peptide hybrid linker； W is absent or is a self-destructing system containing one or more self-destructing groups； L is absent or is a conditionally cleavable moiety Ant is an anthracycline moiety selected from formulas (II), (III), (IV) and (V), where at least one of L, W, Z and RM is present, and the wavy line is Shows binding to conditionally cleavable moiety L, self-destructing system W, linker Z, or reactive moiety RM； R1 is halogen or NR4R5； R2 is OR6, NR7 8, or an optionally substituted group selected from linear or branched C1-C4 alkyl-, NR7R8-C1-C4 alkyl- and R6O-C1-C4 alkyl-； R4 and R5 are independently Hydrogen, monosubstituted benzyl, disubstituted benzyl, or straight or branched C1-C6 alkyl, NR7R8-C1-C6 alkyl-, R6O-C1-C6 alkyl-, R7R8N-C1-C6 alkylcarbonyl-, R6O-C1- An optionally substituted group selected from C6 alkylcarbonyl-, R7R8N-C1-C6 alkoxycarbonyl- and R6O-C1-C6 alkoxycarbonyl-； or R4 and R5 are the nitrogen atom to which they are attached； Together form a heterocyclyl substituted with R4 ′, wherein R4 ′ is hydrogen, linear or A group selected from branched C1-C6 alkyl and NR7R8-C1-C6 alkyl-； R15 is absent or -NR7-C1-C6 alkyl *, -O-C1-C6 alkyl *, -NR7-C1 An optionally substituted divalent group selected from -C6
